Abstracts

QUINOLINIC ACID IS A BIOMARKER OF COVID-19–ASSOCIATED COGNITIVE IMPAIRMENT

COVID-19 infection-associated cognitive and olfaction impairments have an unclear pathogenesis, possibly related to systemic disease severity, hypoxia, or illness-associated anxiety and depression. A biomarker for these neurocognitive changes is lacking. The kynurenine pathway (KP) is an interferon stimulated myeloid cell mediated tryptophan degradation pathway important in immune tolerance, neurotoxicity and vascular injury, that is dysregulated…

CSF AND BLOOD ANALYSES IN PARTICIPANTS WITH POST-COVID-19 NEUROPSYCHIATRIC SYMPTOMS

The pathogenesis of neuropsychiatric symptoms persisting months after acute SARS-CoV-2 infection is poorly understood. We examined clinical and laboratory parameters in participants with post-acute COVID-19 neuropsychiatric symptom to assess for systemic and nervous system immune perturbations. Participants with a history of laboratory confirmed COVID-19 and ongoing neurologic symptoms were enrolled in an observational study that…

TOCILIZUMAB (BIOSIMILAR) USE IN CYTOKINE STORM OF SEVERE COVID-19 PNEUMONIA

Tocilizumab is an IgG1 class humanized monoclonal antibody targeting IL-6 receptor (IL-6R). IL-6 is a key cytokine involved in cytokine storm of severe COVID-19. Tocilizumab down-regulates IL-6 preventing fatal and permanent damage to vital organs, significantly preventing COVID-19 related mortality and morbidity. Therefore, this study aimed to compare the efficacy and safety of Tocilizumab (biosimilar)…

ALTERED GUT MICROBIOTA AND RESPIRATORY DYSFUNCTION 3 MONTHS AFTER SEVERE COVID-19

Although COVID-19 is primarily a respiratory infection, mounting evidence suggests that the GI tract is involved in the disease, with gut barrier dysfunction and gut microbiota alterations being related to disease severity. Whether these alterations persist and associate with long-term respiratory dysfunction is unknown. From the NOR-Solidarity trial (n=181), plasma was collected during hospital admission…

HIV AND SARS-CoV-2 INFECTION AND OUTCOMES IN THE MID-ATLANTIC US

Reports of severity of illness and outcomes of SARS-CoV-2 infection in persons living with HIV (PLWH) vary across cohorts. Limited data exists regarding post-infection complications among PLWH. We examined the clinical characteristics and outcomes among PLWH infected with SARS-CoV-2 compared to an age and race matched cohort in a healthcare system composed of ten academic…

POST-ACUTE SEQUELAE OF SARS-CoV-2 IN NONHOSPITALIZED ACTIV-2 TRIAL PARTICIPANTS

Randomized COVID-19 trials provide opportunities to describe post-acute sequelae of SARS-CoV-2 (PASC)-related symptom burden longitudinally and assess the impact of early use of antivirals on PASC prevalence. ACTIV-2 evaluates safety and efficacy of investigational agents for non-hospitalized adults with mild to moderate COVID-19 in a Phase 2/3 trial. In Phase 2, participants were randomized within…